United Therapeutics Corporation (NASDAQ:UTHR) Receives $533.55 Average Target Price from Brokerages

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have earned an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $539.00.

A number of research analysts have recently commented on the stock. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. UBS Group increased their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. TD Cowen boosted their target price on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th.

United Therapeutics Trading Down 1.4%

Shares of UTHR stock traded down $6.90 during trading hours on Friday, reaching $478.16. The stock had a trading volume of 315,914 shares, compared to its average volume of 388,036. The stock’s fifty day simple moving average is $482.51 and its 200 day simple moving average is $452.28. The firm has a market capitalization of $20.96 billion, a PE ratio of 17.14, a PEG ratio of 1.75 and a beta of 0.84. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $537.19.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same quarter in the prior year, the firm posted $6.19 EPS. United Therapeutics’s revenue was up 7.4% on a year-over-year basis. As a group, equities research analysts anticipate that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Activity

In related news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $496.30, for a total value of $11,166,750.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the sale, the chief financial officer owned 8,142 shares of the company’s stock, valued at approximately $3,896,761.20. The trade was a 72.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 377,184 shares of company stock valued at $183,015,947 in the last three months. 10.30% of the stock is owned by insiders.

Institutional Trading of United Therapeutics

A number of hedge funds have recently made changes to their positions in UTHR. Torren Management LLC bought a new position in United Therapeutics in the fourth quarter valued at $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at about $31,000. Wilmington Savings Fund Society FSB increased its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics during the 4th quarter valued at about $48,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell‑side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid‑range price target, supporting a constructive medium‑term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near‑term weakness even if insiders retain stakes. Read More. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.